RAD Alignment with US FDA for Development of RAD101
Filed with ASX · · 3 pages · English
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Radiopharm receives $8M advance on FY26 R&D tax incentive
- Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
- Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
- Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics